David Pejoski | Co-CEO
Adoram Therapeutics

David Pejoski is Co-CEO of Adoram Therapeutics, a Swiss-based university spin-off company developing breakthrough therapies for cancer and inflammation. With a research background in vaccines and immunology, David has led the preclinical development of novel allosteric modulators that aim to be safer and more effective than conventional small molecule therapies. As a panel moderator at BioTechX 2026, David will host a conversation about AI-powered drug discovery approaches and their development or implementation by small and mid-sized biotech companies.